EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials

Hernando Vargas-Uricoechea, Juan Pablo Frias, Hernando David Vargas-Sierra

Review of Diabetic Studies · 31.03.2023 · 19 (1) · 14-27

DOI: 10.1900/rds.2023.19.14 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Review of Diabetic Studies, erschienen am 31.03.2023. Verfasst von Hernando Vargas-Uricoechea und 2 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Diseases Study Group, Department of Internal Medicine, Universidad del Cauca, Popayán-Colombia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In type 2 diabetes, therapeutic failure to the oral anti diabetics is frequent, the use of schemes with basal insulin or with multiple doses of insulin (basal insulin and short-acting insulins) are a widely accepted way to intensify therapy. The use of GLP-1 receptor agonists is another intensification strategy. The fixedratio combinations with molecules such as insulin degludec + liraglutide, and insulin glargine + lixisenatide have proven useful in intensifying treatment of individuals with type 2 diabetes. The purpose of this review was to evaluate and analyze the results of pivotal studies with both fixed-ratio combinations in individuals with type 2 diabetes, finding that, they are capable of achieving better glycemic control when compared with each of its components separately (with a lower risk of hypoglycemia vs basal insulin and lower risk of gastrointestinal adverse effects vs GLP-1 receptor agonists) in various clinical scenarios, especially in individuals who do not achieve control with oral antidiabetics or who do not achieve control with basal insulin (associated with oral antidiabetics) or in those under management with GLP-1RA plus oral antidiabetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansGlucagon-Like Peptide-1 ReceptorDrug CombinationsHypoglycemic AgentsInsulinLiraglutideBlood GlucoseGlucagon-Like Peptide-1 Receptor Agonists

Substanzen

Glucagon-Like Peptide-1 ReceptorDrug CombinationsHypoglycemic AgentsInsulinLiraglutideBlood GlucoseGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Metabolic Diseases Study Group, Department of Internal Medicine, Universidad del Cauca, Popayán-Colombia.
  • National Research Institute, USA.
  • Metabolic Diseases Study Group, Department of Internal Medicine, Universidad del Cauca, Popayán-Colombia. Fellowship in Endocrinology, Diabetes and Metabolism, Universidad Pontificia Bolivariana, Medellín-Colombia.

Zitieren

APA

Vargas-Uricoechea, H., Frias, J. P., & Vargas-Sierra, H. D. (2023). Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials. Review of Diabetic Studies, 19(1), 14-27. https://doi.org/10.1900/rds.2023.19.14

Vancouver

Vargas-Uricoechea H, Frias JP, Vargas-Sierra HD. Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials. Review of Diabetic Studies. 2023;19(1):14-27. doi:10.1900/rds.2023.19.14

BibTeX
@article{VargasUricoechea2023,
  author = {Vargas-Uricoechea, Hernando and Frias, Juan Pablo and Vargas-Sierra, Hernando David},
  title = {Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials},
  journal = {Review of Diabetic Studies},
  year = {2023},
  volume = {19},
  number = {1},
  pages = {14--27},
  doi = {10.1900/rds.2023.19.14}
}
Kostenlos starten →